Bain, Stephen C.

Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke: Post Hoc Analysis From the LEADER Trial

Verma, S., Poulter, N. R., Bhatt, D. L., Bain, S. C., Buse, J. B., Leiter, L. A., Nauck, M. A., Pratley, R. E., Zinman, B., Ørsted, D. D., et al. (2018) · Circulation

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 127

Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo

Tuttle, K. R., Bosch-Traberg, H., Cherney, D. Z. I., Hadjadj, S., Lawson, J., Mosenzon, O., Rasmussen, S., & Bain, S. C. (2023) · Kidney International

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 124

Effects of liraglutide on cardiovascular outcomes in patients with diabetes with or without heart failure

Marso, S. P., Baeres, F. M. M., Bain, S. C., Goldman, B., Husain, M., Nauck, M. A., Poulter, N. R., Pratley, R. E., Thomsen, A. B., & Buse, J. B. (2020) · Journal of the American College of Cardiology

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 118

Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease: Results of the LEADER Trial

Verma, S., Bhatt, D. L., Bain, S. C., Buse, J. B., Mann, J. F. E., Marso, S. P., Nauck, M. A., Poulter, N. R., Pratley, R. E., Zinman, B., et al. (2018) · Circulation

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 105

Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial

Horn, D. B., Ryan, D. H., Kis, S. G., Alves, B., Mu, Y., Kim, S. G., Aberle, J., Bain, S. C., Allen, S., Sarker, E., et al. (2025) · The Lancet

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 70

Oral semaglutide and cardiovascular outcomes in people with type 2 diabetes, according to SGLT2i use: prespecified analyses of the SOUL randomized trial

Marx, N., Deanfield, J. E., Mann, J. F. E., Arechavaleta, R., Bain, S. C., Bajaj, H. S., Bayer Tanggaard, K., Birkenfeld, A. L., Buse, J. B., Davicevic-Elez, Z., et al. (2025) · Circulation

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 70

Recent advances in understanding the role of glucagon-like peptide 1

Reed, J., Bain, S., & Kanamarlapudi, V. (2020) · F1000Research

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 66

Evaluating the burden of poor glycemic control associated with therapeutic inertia in patients with type 2 diabetes in the UK

Bain, S. C., Bekker Hansen, B., Hunt, B., Chubb, B., & Valentine, W. J. (2020) · Journal of Medical Economics

Diabetes Treatment and ManagementHealth Systems, Economic Evaluations, Quality of Life

Cited by 53

The effect of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials

Leiter, L. A., Bain, S. C., Bhatt, D. L., Buse, J. B., Mazer, C. D., Pratley, R. E., Rasmussen, S., Ripa, M. S., Vrazic, H., & Verma, S. (2020) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementBlood Pressure and Hypertension Studies

Cited by 45

Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK

Viljoen, A., Hoxer, C. S., Johansen, P., Malkin, S., Hunt, B., & Bain, S. C. (2019) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementHealth Systems, Economic Evaluations, Quality of Life

Cited by 45

Effect of structured self‐monitoring of blood glucose, with and without additional TeleCare support, on overall glycaemic control in non‐insulin treated Type 2 diabetes: the SMBG Study, a 12‐month randomized controlled trial

Parsons, S. N., Luzio, S. D., Harvey, J. N., Bain, S. C., Cheung, W. Y., Watkins, A., & Owens, D. R. (2019) · Diabetic Medicine

Diabetes Management and ResearchDiabetes Management and Education

Cited by 39

Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use: Results From the LEADER Trial

Verma, S., Leiter, L. A., Mazer, C. D., Bain, S. C., Buse, J., Marso, S., Nauck, M., Zinman, B., Bosch-Traberg, H., Rasmussen, S., et al. (2018) · Circulation

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 35

Isomaltulose Improves Glycemia and Maintains Run Performance in Type 1 Diabetes

BRACKEN, R. M., PAGE, R., GRAY, B., KILDUFF, L. P., WEST, D. J., STEPHENS, J. W., & BAIN, S. C. (2012) · Medicine & Science in Sports & Exercise

Diabetes Management and ResearchMuscle metabolism and nutrition

Cited by 32

Real-World Clinical Experience of Semaglutide in Secondary Care Diabetes: A Retrospective Observational Study

Williams, D. M., Ruslan, A. M., Khan, R., Vijayasingam, D., Iqbal, F., Shaikh, A., Lim, J., Chudleigh, R., Peter, R., Udiawar, M., et al. (2021) · Diabetes Therapy

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 31

Molecular Characterisation of Small Molecule Agonists Effect on the Human Glucagon Like Peptide-1 Receptor Internalisation

Thompson, A., Stephens, J. W., Bain, S. C., & Kanamarlapudi, V. (2016) · PLOS ONE

Receptor Mechanisms and SignalingDiabetes Treatment and Management

Cited by 19

Mechanism of cardiovascular disease benefit of glucagon-like peptide 1 agonists

Reed, J., Kanamarlapudi, V., & Bain, S. (2018) · Cardiovascular Endocrinology & Metabolism

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 16

Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6

Husain, M., Consoli, A., De Remigis, A., Pettersson Meyer, A. S., Rasmussen, S., & Bain, S. (2022) · Cardiovascular Diabetology

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 16

Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond

Viljoen, A., & Bain, S. C. (2023) · Endocrinology and Metabolism

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 11

Meeting the Challenge of Virtual Diabetes Care: A Consensus Viewpoint on the Positioning and Value of Oral Semaglutide in Routine Clinical Practice

Evans, M., Morgan, A. R., Bain, S. C., Davies, S., Hicks, D., Brown, P., Yousef, Z., Dashora, U., Viljoen, A., Beba, H., et al. (2022) · Diabetes Therapy

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 10